~~<i id='B02F48D851'><strike id='B02F48D851'><tt id='B02F48D851'><pre id='B02F48D851'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：entertainment 2025-10-01 22:58:27 - browse：19259

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： It was time to plan for my old age. If only I could stop crying

hotspot

knowledge

explore

Wikipedia

focus

leisure time

NOAHSEELAM/AFPviaGettyImagesGoogle’sgenerativeAIsystemproveditcananswermedicalexamquestions.Butnowth

WSS

340B reform proposal comes out of Senate working group

A protest over insulin prices is seen as a fight for life

Padmanee Sharma of MD Anderson at center of lawsuit over credit

NFL doctors' conflicts of interest could endanger players, report says

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

hotspot

comprehensive

hotspot

The high cost of giving birth even with insurance

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Dobbs anniversary: the lost opportunity of abortion as health care

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Hepatitis C has a cure — but many Americans still lack access to it

Failure, not just success, should guide future doctors

Jerome Adams on the need for new antivirals for Covid

How CRISPR works, explained in two minutes

23andMe had bad news about my health. I wish a person had delivered it

'Brian's Song' at 50 still offers lessons about cancer for today

knowledge

The CDC's new social media misinformation war

AI gets buy

Feed a cold, starve a fever? Here’s what science says

Slovenia has suffered its worst

Feed a cold, starve a fever? Here’s what science says

Readout Newsletter: Amgen, Regeneron, BGI Group and more

explore

Wikipedia

focus

leisure time